Multiple Myeloma Articles | Page 3

Triplet Regimens, Maintenance Therapy New Standards for Multiple Myeloma
Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.
Personalized Medicine Moving to Forefront of Hematologic Malignancies
Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.
FDA Grants BCMA Antibody-Drug Conjugate Breakthrough Status for Myeloma
The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.
Expert Sheds Light on Role of Combinations, Transplant in Myeloma
Jayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.
Carfilzomib Effective in Myeloma at Less Frequent, Higher Dose
Higher-dose, once-weekly carfilzomib (Kyprolis) demonstrated superior efficacy for patients with relapsed/refractory multiple myeloma compared with a lower-dose, twice-weekly regimen.
Lenalidomide Maintenance Post-ASCT Improves Survival in Myeloma
Maintenance therapy with lenalidomide following autologous stem-cell transplantation conferred a survival benefit for patients with newly diagnosed multiple myeloma.
VCD Induction Induces High Response Rates in Myeloma
Induction therapy with bortezomib, cyclophosphamide, and dexamethasone induced strong response rates in treatment-naïve patients with multiple myeloma.
Strategies Explored to Enhance Treatment of Elderly Myeloma Patients
Ashley Rosko, MD, discusses available therapies, others under investigation, and supportive care methods being utilized for patients with multiple myeloma.
Treatment for Relapsed/Refractory Multiple Myeloma Based on Biology, Time to Relapse
The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.
Managing Newly-Diagnosed Multiple Myeloma
Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.
Publication Bottom Border
Border Publication